{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T15:10:09Z","timestamp":1767625809072},"reference-count":176,"publisher":"Oxford University Press (OUP)","issue":"5","content-domain":{"domain":["eje.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2018,11]]},"abstract":"<jats:p>Medical treatment of pituitary tumours may present important challenges in the presence of resistance to first-line therapy. In this setting, the availability of specific markers of responsiveness\/resistance could be helpful to provide tailored patients\u2019 treatment. Pituitary receptor profiling has emerged as a potentially useful tool for predicting the response to specific pituitary-directed medical therapy, mainly somatostatin analogues and dopamine agonists. However, its utility is not always straightforward. In fact, agonist-receptor coupling to the consequent biological response is complex and sometimes jeopardizes the understanding of the molecular basis of pharmacological resistance. Defective expression of pituitary receptors, genetic alterations, truncated variants, impaired signal transduction or involvement of other proteins, such as cytoskeleton proteins or the aryl hydrocarbon receptor-interacting protein amongst others, have been linked to differential tumour phenotype or treatment responsiveness with conflicting results, keeping the debate on the utility of pituitary receptor profiling open. Why does this occur? How can we overcome the difficulties? Is there a true role for pituitary receptor profiling in the near future? All authors of this debate article agree on the need of prospective studies using standardized methods in order to assess the efficacy of receptor profiling as a reliable clinical predictive factor.<\/jats:p>","DOI":"10.1530\/eje-18-0549","type":"journal-article","created":{"date-parts":[[2018,8,23]],"date-time":"2018-08-23T13:04:22Z","timestamp":1535029462000},"page":"D15-D25","update-policy":"http:\/\/dx.doi.org\/10.1530\/crossmarkpolicy-1","source":"Crossref","is-referenced-by-count":8,"title":["Is receptor profiling useful for predicting pituitary therapy?"],"prefix":"10.1093","volume":"179","author":[{"given":"Monica","family":"Marazuela","sequence":"first","affiliation":[{"name":"1Department of Endocrinology, Hospital Universitario La Princesa, Instituto de Investigaci\u00f3n Princesa, Universidad Aut\u00f3noma de Madrid, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana M","family":"Ramos-Lev\u00ed","sequence":"additional","affiliation":[{"name":"1Department of Endocrinology, Hospital Universitario La Princesa, Instituto de Investigaci\u00f3n Princesa, Universidad Aut\u00f3noma de Madrid, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia","family":"Borges de Souza","sequence":"additional","affiliation":[{"name":"2Section of Endocrinology and Internal Medicine, Department of Medical Sciences, University of Ferrara, Ferrara, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Chiara","family":"Zatelli","sequence":"additional","affiliation":[{"name":"2Section of Endocrinology and Internal Medicine, Department of Medical Sciences, University of Ferrara, Ferrara, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","reference":[{"key":"ref1611","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1046\/j.1365-2362.2001.00786.x","article-title":"Somatostatin receptor subtype 2 and 5 in human GH-secreting pituitary adenomas: analysis of gene sequence and mRNA expression","volume":"31","year":"2001","journal-title":"European Journal of Clinical Investigation"},{"key":"ref1231","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1007\/BF03347378","article-title":"Dissociation between tumor shrinkage and hormonal response during somatostatin analog treatment in an acromegalic patient: preferential expression of somatostatin receptor subtype 3","volume":"29","year":"2006","journal-title":"Journal of Endocrinological Investigation"},{"key":"ref1311","first-page":"38","article-title":"Low somatostatin receptor subtype 2, but not dopamine receptor subtype 2 expression predicts the lack of biochemical response of somatotropinomas to treatment with somatostatin analogs","volume":"36","year":"2013","journal-title":"Journal of Endocrinological Investigation"},{"key":"ref1621","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.endonu.2014.05.006","article-title":"Cytoplasmic expression of SSTR2 and 5 by immunohistochemistry and by RT\/PCR is not associated with the pharmacological response to octreotide","volume":"61","year":"2014","journal-title":"Endocrinologia y Nutricion"},{"key":"ref1571","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1038\/tpj.2008.1","article-title":"Dopamine D2 receptor gene polymorphisms and response to cabergoline therapy in patients with prolactin-secreting pituitary adenomas","volume":"8","year":"2008","journal-title":"Pharmacogenomics Journal"},{"key":"ref311","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1507\/endocrj.K08E-305","article-title":"Analyses of factors influencing the acute effect of octreotide in Growth Hormone-secreting adenomas","volume":"56","year":"2009","journal-title":"Endocrine Journal"},{"key":"ref1171","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1210\/jc.2009-2247","article-title":"A potential inhibitory role for the new truncated variant of somatostatin receptor 5, sst5TMD4, in pituitary adenomas poorly responsive to somatostatin analogs","volume":"95","year":"2010","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"ref1461","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1111\/cen.12684","article-title":"Dopamine receptor subtype 2 expression profile in nonfunctioning pituitary adenomas and in vivo response to cabergoline therapy","volume":"82","year":"2015","journal-title":"Clinical Endocrinology"},{"key":"ref711","first-page":"3455","article-title":"Expression and localization of somatostatin receptor SSTR1, SSTR2, and SSTR3 messenger RNAs in primary human tumors using in situ hybridization","volume":"54","year":"1994","journal-title":"Cancer Research"},{"key":"ref1361","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1530\/EJE-15-0832","article-title":"Factors predicting pasireotide responsiveness in somatotroph pituitary adenomas resistant to first-generation somatostatin analogues: an immunohistochemical study","volume":"174","year":"2016","journal-title":"European Journal of Endocrinology"},{"key":"ref1601","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1007\/BF03351043","article-title":"Expression of somatostatin receptors on human pituitary adenomas in vivo and ex vivo","volume":"24","year":"2001","journal-title":"Journal of Endocrinological Investigation"},{"key":"ref131","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1007\/s12020-015-0594-x","article-title":"The expression of the truncated isoform of somatostatin receptor subtype 5 associates with aggressiveness in medullary thyroid carcinoma cells","volume":"50","year":"2015","journal-title":"Endocrine"},{"key":"ref431","first-page":"38","article-title":"Low somatostatin receptor subtype 2, but not dopamine receptor subtype 2 expression predicts the lack of biochemical response of somatotropinomas to treatment with somatostatin analogs","volume":"36","year":"2013","journal-title":"Journal of Endocrinological Investigation"},{"key":"ref1501","first-page":"1369","article-title":"Dopamine agonist\u2013resistant prolactinomas","volume":"114","year":"2011","journal-title":"Journal of Neurological Surgery"},{"key":"ref231","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1038\/nrendo.2011.37","article-title":"Medical treatment of prolactinomas","volume":"7","year":"2011","journal-title":"Nature Reviews Endocrinology"},{"key":"ref1241","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1210\/er.2010-0002","article-title":"Resistance to somatostatin analogs in acromegaly","volume":"32","year":"2011","journal-title":"Endocrine Reviews"},{"key":"ref1411","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s11102-014-0582-9","article-title":"Up-to 5-year efficacy of pasireotide in a patient with Cushing\u2019s disease and pre-existing diabetes: literature review and clinical practice considerations","volume":"18","year":"2015","journal-title":"Pituitary"},{"key":"ref601","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1210\/jc.2010-1692","article-title":"Diagnosis and treatment of hyperprolactinemia: an Endocrine Society Clinical Practice Guideline","volume":"96","year":"2011","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"ref1641","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1210\/jc.2013-2145","article-title":"Expression of a but not of or in somatotroph adenomas assessed by monoclonal antibodies was reduced by octreotide and correlated with the acute and long - term effects of octreotide of and https org","author":"Casar","journal-title":"Journal Clinical Endocrinology Metabolism"},{"key":"ref71","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1210\/er.2000-0001","article-title":"The pathophysiological consequences of somatostatin receptor internalization and resistance","volume":"24","year":"2003","journal-title":"Endocrine Reviews"},{"key":"ref1181","first-page":"1416","article-title":"Preoperative octreotide treatment of Growth Hormone-secreting and clinically nonfunctioning pituitary macroadenomas: effect on tumor volume and lack of correlation with immunohistochemistry and somatostatin receptor scintigraphy","volume":"79","year":"1994","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"ref1441","first-page":"111","article-title":"SSTR3 is a putative target for the medical treatment of gonadotroph adenomas of the pituitary","volume":"22","year":"2015","journal-title":"Endocrine-Related Cancer"},{"key":"ref291","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1210\/jc.2009-2247","article-title":"A potential inhibitory role for the new truncated variant of somatostatin receptor 5, sst5TMD4, in pituitary adenomas poorly responsive to somatostatin analogs","volume":"95","year":"2010","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"ref971","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1385\/ENDO:14:3:329","article-title":"Dopamine D2 receptor gene expression in human adenohypophysial adenomas","volume":"14","year":"2001","journal-title":"Endocrine"},{"key":"ref801","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.tem.2012.11.007","article-title":"Novel pathway for somatostatin analogs in patients with acromegaly","volume":"24","year":"2013","journal-title":"Trends in Endocrinology and Metabolism"},{"key":"ref591","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.mce.2007.12.008","article-title":"Relevance of coexpression of somatostatin and dopamine D2 receptors in pituitary adenomas","volume":"286","year":"2008","journal-title":"Molecular and Cellular Endocrinology"},{"key":"ref1211","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1530\/eje.0.1360369","article-title":"Results of somatostatin receptor scintigraphy do not predict pituitary tumor volume- and hormone-response to octreotide therapy and do not correlate with tumor histology.","volume":"136","year":"1997","journal-title":"European Journal of Endocrinology"},{"key":"ref211","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/S2213-8587(14)70169-X","article-title":"Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial","volume":"2","year":"2014","journal-title":"Lancet Diabetes and Endocrinology"},{"key":"ref581","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1111\/cen.12684","article-title":"Dopamine receptor subtype 2 expression profile in nonfunctioning pituitary adenomas and in vivo response to cabergoline therapy","volume":"82","year":"2015","journal-title":"Clinical Endocrinology"},{"key":"ref851","doi-asserted-by":"crossref","first-page":"2334","DOI":"10.1210\/jc.2009-2197","article-title":"The expression of E-cadherin in somatotroph pituitary adenomas is related to tumor size, invasiveness, and somatostatin analog response","volume":"95","year":"2010","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"ref751","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1530\/JOE-16-0332","article-title":"Octreotide and pasireotide (dis)similarly inhibit pituitary tumor cells in vitro","volume":"231","year":"2016","journal-title":"Journal of Endocrinology"},{"key":"ref1341","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.ghir.2015.07.003","article-title":"Truncated somatostatin receptor 5 may modulate therapy response to somatostatin analogues \u2013 observations in two patients with acromegaly and severe headache","volume":"25","year":"2015","journal-title":"Growth Hormone and IGF Research"},{"key":"ref1351","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1210\/jc.2017-00135","article-title":"In vitro head-to-head comparison between octreotide and pasireotide in GH-secreting pituitary adenomas","volume":"102","year":"2017","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"ref761","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1210\/jc.2013-2145","article-title":"Expression of a but not of or in somatotroph adenomas assessed by monoclonal antibodies was reduced by octreotide and correlated with the acute and long - term effects of octreotide of and https org","author":"Casar","journal-title":"Journal Clinical Endocrinology Metabolism"},{"key":"ref611","first-page":"1","article-title":"of of Practice guidelines for the management of aggressive pituitary tumours and carcinomas of https org","journal-title":"European Society Endocrinology European Society Endocrinology Clinical European Journal Endocrinology"},{"key":"ref931","doi-asserted-by":"crossref","first-page":"19762","DOI":"10.1074\/jbc.M110373200","article-title":"Heterodimerization of somatostatin and opioid receptors cross-modulates phosphorylation, internalization, and desensitization","volume":"277","year":"2002","journal-title":"Journal of Biological Chemistry"},{"key":"ref941","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.cellsig.2008.11.012","article-title":"Somatostatin receptors 1 and 5 heterodimerize with epidermal growth factor receptor: agonist-dependent modulation of the downstream MAPK signalling pathway in breast cancer cells","volume":"21","year":"2009","journal-title":"Cellular Signalling"},{"key":"ref491","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1210\/jc.2008-2101","article-title":"Coexpression of dopamine and somatostatin receptor subtypes in corticotroph adenomas","volume":"94","year":"2009","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"ref1671","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1111\/j.1365-2265.2007.03065.x","article-title":"The clinical response to somatostatin analogues in acromegaly correlates to the somatostatin receptor subtype 2a protein expression of the adenoma","volume":"68","year":"2008","journal-title":"Clinical Endocrinology"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"2634","DOI":"10.1210\/jc.2008-2564","article-title":"Identification and characterization of two novel truncated but functional isoforms of the somatostatin receptor subtype 5 differentially present in pituitary tumors","volume":"94","year":"2009","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"ref241","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1677\/ERC-08-0181","article-title":"Medical therapy for clinically non-functioning pituitary adenomas","volume":"15","year":"2008","journal-title":"Endocrine-Related Cancer"},{"key":"ref191","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1007\/s11102-014-0618-1","article-title":"Pasireotide can induce sustained decreases in urinary cortisol and provide clinical benefit in patients with Cushing\u2019s disease: results from an open-ended, open-label extension trial","volume":"18","year":"2015","journal-title":"Pituitary"},{"key":"ref391","first-page":"396","article-title":"Somatostatin and its analog lanreotide inhibit the proliferation of dispersed human non-functioning pituitary adenoma cells in vitro","volume":"141","year":"1999","journal-title":"European Journal of Endocrinology"},{"key":"ref1511","doi-asserted-by":"crossref","first-page":"4721","DOI":"10.1210\/jc.2007-2758","article-title":"Prospective study of high-dose cabergoline treatment of prolactinomas in 150 patients","volume":"93","year":"2008","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"ref1531","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1530\/EJE-13-0503","article-title":"Giant prolactinomas in women","volume":"170","year":"2014","journal-title":"European Journal of Endocrinology"},{"key":"ref261","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1210\/jc.2010-2443","article-title":"Place of cabergoline in acromegaly: a meta-analysis","volume":"96","year":"2011","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"ref1471","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.mce.2007.12.008","article-title":"Relevance of coexpression of somatostatin and dopamine D2 receptors in pituitary adenomas","volume":"286","year":"2008","journal-title":"Molecular and Cellular Endocrinology"},{"key":"ref1481","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1210\/jc.2010-1692","article-title":"Diagnosis and treatment of hyperprolactinemia: an Endocrine Society Clinical Practice Guideline","volume":"96","year":"2011","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"ref991","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.canlet.2015.01.037","article-title":"Truncated somatostatin receptor variant sst5TMD4 confers aggressive features (proliferation, invasion and reduced octreotide response) to somatotropinomas","volume":"359","year":"2015","journal-title":"Cancer Letters"},{"key":"ref1731","doi-asserted-by":"crossref","first-page":"2334","DOI":"10.1210\/jc.2009-2197","article-title":"The expression of E-cadherin in somatotroph pituitary adenomas is related to tumor size, invasiveness, and somatostatin analog response","volume":"95","year":"2010","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"ref1681","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.tem.2012.11.007","article-title":"Novel pathway for somatostatin analogs in patients with acromegaly","volume":"24","year":"2013","journal-title":"Trends in Endocrinology and Metabolism"},{"key":"ref81","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1210\/jc.2004-2156","article-title":"Somatostatin analogs in vitro effects in a Growth Hormone-releasing hormone-secreting bronchial carcinoid","volume":"90","year":"2005","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"ref691","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1038\/tpj.2008.1","article-title":"Dopamine D2 receptor gene polymorphisms and response to cabergoline therapy in patients with prolactin-secreting pituitary adenomas","volume":"8","year":"2008","journal-title":"Pharmacogenomics Journal"},{"key":"ref501","doi-asserted-by":"publisher","first-page":"2005289","DOI":"10.1152\/ajpendo.00004.2005","article-title":"van der HoekJWaaijersMvan KoetsveldPMSprij - MooijDFeeldersRASchmidHASchoeffterPHoyerDCerviaDTaylorJEDistinct functional properties of native somatostatin receptor subtype compared with subtype in the regulation of ACTH release by corticotroph tumor cells","journal-title":"American Journal Physiology Endocrinology Metabolism"},{"key":"ref671","first-page":"50","article-title":"Gender differences in macroprolactinomas: study of clinical features, outcome of patients and Ki-67 expression in tumor tissue","volume-title":"Frontiers of Hormone Research","year":"2010"},{"key":"ref631","doi-asserted-by":"crossref","first-page":"4721","DOI":"10.1210\/jc.2007-2758","article-title":"Prospective study of high-dose cabergoline treatment of prolactinomas in 150 patients","volume":"93","year":"2008","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"ref881","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.ecl.2014.10.010","article-title":"Outcomes of endoscopic transsphenoidal pituitary surgery","volume":"44","year":"2015","journal-title":"Endocrinology and Metabolism Clinics of North America"},{"key":"ref301","first-page":"1416","article-title":"Preoperative octreotide treatment of Growth Hormone-secreting and clinically nonfunctioning pituitary macroadenomas: effect on tumor volume and lack of correlation with immunohistochemistry and somatostatin receptor scintigraphy","volume":"79","year":"1994","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"ref521","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1056\/NEJMoa1105743","article-title":"A 12-month Phase 3 study of pasireotide in Cushing\u2019s disease.","volume":"366","year":"2012","journal-title":"New England Journal of Medicine"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"19762","DOI":"10.1074\/jbc.M110373200","article-title":"Heterodimerization of somatostatin and opioid receptors cross-modulates phosphorylation, internalization, and desensitization","volume":"277","year":"2002","journal-title":"Journal of Biological Chemistry"},{"key":"ref121","doi-asserted-by":"crossref","first-page":"e85527","DOI":"10.1371\/journal.pone.0085527","article-title":"The truncated isoform of somatostatin receptor5 (sst5TMD4) is associated with poorly differentiated thyroid cancer","volume":"9","year":"2014","journal-title":"PLoS ONE"},{"key":"ref451","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1007\/s11102-012-0445-1","article-title":"Growth Hormone granulation pattern and somatostatin receptor subtype 2A correlate with postoperative somatostatin receptor ligand response in acromegaly: a large single center experience","volume":"16","year":"2013","journal-title":"Pituitary"},{"key":"ref481","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1530\/EJE-15-0832","article-title":"Factors predicting pasireotide responsiveness in somatotroph pituitary adenomas resistant to first-generation somatostatin analogues: an immunohistochemical study","volume":"174","year":"2016","journal-title":"European Journal of Endocrinology"},{"key":"ref471","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1210\/jc.2017-00135","article-title":"In vitro head-to-head comparison between octreotide and pasireotide in GH-secreting pituitary adenomas","volume":"102","year":"2017","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"ref641","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1530\/EJE-09-0012","article-title":"Characterization of resistance to the prolactin-lowering effects of cabergoline in macroprolactinomas: a study in 122 patients","volume":"160","year":"2009","journal-title":"European Journal of Endocrinology"},{"key":"ref961","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1210\/jc.2004-2156","article-title":"Somatostatin analogs in vitro effects in a Growth Hormone-releasing hormone-secreting bronchial carcinoid","volume":"90","year":"2005","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"ref791","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1111\/j.1365-2265.2007.03065.x","article-title":"The clinical response to somatostatin analogues in acromegaly correlates to the somatostatin receptor subtype 2a protein expression of the adenoma","volume":"68","year":"2008","journal-title":"Clinical Endocrinology"},{"key":"ref1101","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0303-7207(03)00236-3","article-title":"Anti-proliferative effects and cell death mediated by two isoforms of dopamine D2 receptors in pituitary tumor cells","volume":"206","year":"2003","journal-title":"Molecular and Cellular Endocrinology"},{"key":"ref1281","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1210\/jc.2003-031344","article-title":"The novel somatostatin analog SOM230 is a potent inhibitor of hormone release by Growth Hormone- and prolactin-secreting pituitary adenomas in vitro","volume":"89","year":"2004","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"ref271","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1507\/endocrj.51.227","article-title":"Somatostatin (SRIF) receptor subtype 2 and 5 gene expression in Growth Hormone-secreting pituitary adenomas: the relationship with endogenous srif activity and response to octreotide","volume":"51","year":"2004","journal-title":"Endocrine Journal"},{"key":"ref701","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1530\/EJE-07-0806","article-title":"Somatostatinergic ligands in dopamine-sensitive and -resistant prolactinomas","volume":"158","year":"2008","journal-title":"European Journal of Endocrinology"},{"key":"ref361","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1210\/er.2010-0002","article-title":"Resistance to somatostatin analogs in acromegaly","volume":"32","year":"2011","journal-title":"Endocrine Reviews"},{"key":"ref1381","doi-asserted-by":"publisher","first-page":"2005289","DOI":"10.1152\/ajpendo.00004.2005","article-title":"van der HoekJWaaijersMvan KoetsveldPMSprij - MooijDFeeldersRASchmidHASchoeffterPHoyerDCerviaDTaylorJEDistinct functional properties of native somatostatin receptor subtype compared with subtype in the regulation of ACTH release by corticotroph tumor cells","journal-title":"American Journal Physiology Endocrinology Metabolism"},{"key":"ref01","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.ecl.2014.10.010","article-title":"Outcomes of endoscopic transsphenoidal pituitary surgery","volume":"44","year":"2015","journal-title":"Endocrinology and Metabolism Clinics of North America"},{"key":"ref101","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1530\/eje.1.02313","article-title":"Quantitative analysis of somatostatin receptor subtype (SSTR1-5) gene expression levels in somatotropinomas and non-functioning pituitary adenomas","volume":"156","year":"2007","journal-title":"European Journal of Endocrinology"},{"key":"ref1451","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1210\/jc.2008-1826","article-title":"Expression analysis of dopamine receptor subtypes in normal human pituitaries, nonfunctioning pituitary adenomas and somatotropinomas, and the association between dopamine and somatostatin receptors with clinical response to octreotide-LAR in acromegaly","volume":"94","year":"2009","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"ref1021","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.tem.2009.12.003","article-title":"Pituitary somatostatin receptor signaling","volume":"21","year":"2010","journal-title":"Trends in Endocrinology and Metabolism"},{"key":"ref1061","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1507\/endocrj.EJ14-0118","article-title":"Short-term preoperative octreotide treatment for TSH-secreting pituitary adenoma","volume":"62","year":"2015","journal-title":"Endocrine Journal"},{"key":"ref461","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.ghir.2015.07.003","article-title":"Truncated somatostatin receptor 5 may modulate therapy response to somatostatin analogues \u2013 observations in two patients with acromegaly and severe headache","volume":"25","year":"2015","journal-title":"Growth Hormone and IGF Research"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1006\/frne.1999.0183","article-title":"Somatostatin and its receptor family","volume":"20","year":"1999","journal-title":"Frontiers in Neuroendocrinology"},{"key":"ref1741","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1530\/EJE-11-0656","article-title":"Resistance to dopamine agonists in prolactinoma is correlated with reduction of dopamine D2 receptor long isoform mRNA levels","volume":"166","year":"2012","journal-title":"European Journal of Endocrinology"},{"key":"ref91","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1385\/ENDO:14:3:329","article-title":"Dopamine D2 receptor gene expression in human adenohypophysial adenomas","volume":"14","year":"2001","journal-title":"Endocrine"},{"key":"ref561","first-page":"111","article-title":"SSTR3 is a putative target for the medical treatment of gonadotroph adenomas of the pituitary","volume":"22","year":"2015","journal-title":"Endocrine-Related Cancer"},{"key":"ref901","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1006\/frne.1999.0183","article-title":"Somatostatin and its receptor family","volume":"20","year":"1999","journal-title":"Frontiers in Neuroendocrinology"},{"key":"ref1161","first-page":"295","article-title":"Quantitative analysis of somatostatin receptor subtypes (1\u20135) gene expression levels in somatotropinomas and correlation to in vivo hormonal and tumor volume responses to treatment with octreotide LAR","year":"2008","journal-title":"European Journal of Endocrinology"},{"key":"ref1631","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1530\/JOE-16-0332","article-title":"Octreotide and pasireotide (dis)similarly inhibit pituitary tumor cells in vitro","volume":"231","year":"2016","journal-title":"Journal of Endocrinology"},{"key":"ref921","doi-asserted-by":"crossref","first-page":"14027","DOI":"10.1074\/jbc.M006084200","article-title":"Homo- and heterodimerization of somatostatin receptor subtypes. Inactivation of sst3 receptor function by heterodimerization with sst2A","volume":"276","year":"2001","journal-title":"Journal of Biological Chemistry"},{"key":"ref981","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1530\/eje.1.02313","article-title":"Quantitative analysis of somatostatin receptor subtype (SSTR1-5) gene expression levels in somatotropinomas and non-functioning pituitary adenomas","volume":"156","year":"2007","journal-title":"European Journal of Endocrinology"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"14027","DOI":"10.1074\/jbc.M006084200","article-title":"Homo- and heterodimerization of somatostatin receptor subtypes. Inactivation of sst3 receptor function by heterodimerization with sst2A","volume":"276","year":"2001","journal-title":"Journal of Biological Chemistry"},{"key":"ref1131","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1159\/000317716","article-title":"Medical treatment in Cushing\u2019s syndrome: dopamine agonists and cabergoline","volume":"92","year":"2010","journal-title":"Neuroendocrinology"},{"key":"ref1291","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1007\/s12022-007-9004-0","article-title":"Immunohistochemical detection of somatostatin receptor (sstr) subtypes 2A and 5 in pituitary adenoma from acromegalic patients: good correlation with preoperative response to octreotide","volume":"18","year":"2007","journal-title":"Endocrine Pathology"},{"key":"ref541","doi-asserted-by":"crossref","first-page":"2797","DOI":"10.1210\/jc.2002-021825","article-title":"Somatostatin receptor Subtype 1 selective activation in human growth hormone (GH)- and prolactin (PRL)-secreting pituitary adenomas: effects on cell viability, GH, and PRL secretion","volume":"88","year":"2003","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"ref1091","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/S2213-8587(14)70169-X","article-title":"Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial","volume":"2","year":"2014","journal-title":"Lancet Diabetes and Endocrinology"},{"key":"ref1151","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1507\/endocrj.51.227","article-title":"Somatostatin (SRIF) receptor subtype 2 and 5 gene expression in Growth Hormone-secreting pituitary adenomas: the relationship with endogenous srif activity and response to octreotide","volume":"51","year":"2004","journal-title":"Endocrine Journal"},{"key":"ref1261","first-page":"2759","article-title":"Impact of gsp oncogene on the expression of genes coding for Gs\u03b1, Pit-1, Gi2\u03b1, and somatostatin receptor 2 in human somatotroph adenomas: involvement in octreotide sensitivity","volume":"84","year":"1999","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"ref251","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1159\/000317716","article-title":"Medical treatment in Cushing\u2019s syndrome: dopamine agonists and cabergoline","volume":"92","year":"2010","journal-title":"Neuroendocrinology"},{"key":"ref811","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1055\/s-0034-1384520","article-title":"Filamin A in somatostatin and dopamine receptor regulation in pituitary and the role of cAMP\/PKA dependent phosphorylation","volume":"46","year":"2014","journal-title":"Hormone and Metabolic Research"},{"key":"ref1271","first-page":"396","article-title":"Somatostatin and its analog lanreotide inhibit the proliferation of dispersed human non-functioning pituitary adenoma cells in vitro","volume":"141","year":"1999","journal-title":"European Journal of Endocrinology"},{"key":"ref1071","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1007\/s11102-014-0618-1","article-title":"Pasireotide can induce sustained decreases in urinary cortisol and provide clinical benefit in patients with Cushing\u2019s disease: results from an open-ended, open-label extension trial","volume":"18","year":"2015","journal-title":"Pituitary"},{"key":"ref1371","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1210\/jc.2008-2101","article-title":"Coexpression of dopamine and somatostatin receptor subtypes in corticotroph adenomas","volume":"94","year":"2009","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"ref911","doi-asserted-by":"crossref","first-page":"7862","DOI":"10.1074\/jbc.275.11.7862","article-title":"Subtypes of the somatostatin receptor assemble as functional homo- and heterodimers","volume":"275","year":"2000","journal-title":"Journal of Biological Chemistry"},{"key":"ref1121","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1677\/ERC-08-0181","article-title":"Medical therapy for clinically non-functioning pituitary adenomas","volume":"15","year":"2008","journal-title":"Endocrine-Related Cancer"},{"key":"ref351","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1007\/BF03347378","article-title":"Dissociation between tumor shrinkage and hormonal response during somatostatin analog treatment in an acromegalic patient: preferential expression of somatostatin receptor subtype 3","volume":"29","year":"2006","journal-title":"Journal of Endocrinological Investigation"},{"key":"ref331","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1530\/eje.0.1360369","article-title":"Results of somatostatin receptor scintigraphy do not predict pituitary tumor volume- and hormone-response to octreotide therapy and do not correlate with tumor histology.","volume":"136","year":"1997","journal-title":"European Journal of Endocrinology"},{"key":"ref1041","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1210\/jc.2008-1919","article-title":"Differential effects of octreotide and pasireotide on somatostatin receptor internalization and trafficking in vitro","volume":"94","year":"2009","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"ref871","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1210\/jc.2011-2902","article-title":"Filamin-A is essential for dopamine d2 receptor expression and signaling in tumorous lactotrophs","volume":"97","year":"2012","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"ref321","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1210\/jc.2007-1986","article-title":"Selective loss of somatostatin receptor 2 in octreotide-resistant Growth Hormone-secreting adenomas","volume":"93","year":"2008","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"ref1191","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1507\/endocrj.K08E-305","article-title":"Analyses of factors influencing the acute effect of octreotide in Growth Hormone-secreting adenomas","volume":"56","year":"2009","journal-title":"Endocrine Journal"},{"key":"ref1111","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1038\/nrendo.2011.37","article-title":"Medical treatment of prolactinomas","volume":"7","year":"2011","journal-title":"Nature Reviews Endocrinology"},{"key":"ref341","first-page":"1252","article-title":"Somatostatin receptor scintigraphy in pituitary adenomas: a somatostatin receptor density index can predict hormonal and tumoral efficacy of octreotide in vivo","volume":"40","year":"1999","journal-title":"Journal of Nuclear Medicine"},{"key":"ref531","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s11102-014-0582-9","article-title":"Up-to 5-year efficacy of pasireotide in a patient with Cushing\u2019s disease and pre-existing diabetes: literature review and clinical practice considerations","volume":"18","year":"2015","journal-title":"Pituitary"},{"key":"ref551","doi-asserted-by":"crossref","first-page":"5181","DOI":"10.1210\/jc.2003-031954","article-title":"Evidence for differential effects of selective somatostatin receptor subtype agonists on beta-subunit and chromogranin A secretion and on cell viability in human nonfunctioning pituitary adenomas in vitro","volume":"89","year":"2004","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"ref141","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.tem.2009.12.003","article-title":"Pituitary somatostatin receptor signaling","volume":"21","year":"2010","journal-title":"Trends in Endocrinology and Metabolism"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.cellsig.2008.11.012","article-title":"Somatostatin receptors 1 and 5 heterodimerize with epidermal growth factor receptor: agonist-dependent modulation of the downstream MAPK signalling pathway in breast cancer cells","volume":"21","year":"2009","journal-title":"Cellular Signalling"},{"key":"ref831","first-page":"1","article-title":"BIM-23A760 influences key functional endpoints in pituitary adenomas and normal pituitaries: molecular mechanisms underlying the differential response in adenomas","volume":"7","year":"2017","journal-title":"Scientific Reports"},{"key":"ref771","first-page":"9606985","article-title":"Expression of somatostatin receptor 2 in Somatotropinoma correlated with the short-term efficacy of somatostatin analogues","volume":"2017","year":"2017","journal-title":"International Journal of Endocrinology"},{"key":"ref1031","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.mce.2007.09.006","article-title":"Pasireotide (SOM230): development, mechanism of action and potential applications","volume":"286","year":"2008","journal-title":"Molecular and Cellular Endocrinology"},{"key":"ref1661","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s11102-009-0175-1","article-title":"Acromegaly: correlation between expression of somatostatin receptor subtypes and response to octreotide-lar treatment","volume":"12","year":"2009","journal-title":"Pituitary"},{"key":"ref781","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s11102-009-0175-1","article-title":"Acromegaly: correlation between expression of somatostatin receptor subtypes and response to octreotide-lar treatment","volume":"12","year":"2009","journal-title":"Pituitary"},{"key":"ref1721","doi-asserted-by":"crossref","first-page":"4715","DOI":"10.1210\/en.2013-1672","article-title":"\u03b2-Arrestin 1 and 2 and G protein-coupled receptor kinase 2 expression in pituitary adenomas: role in the regulation of response to somatostatin analogue treatment in patients with acromegaly","volume":"154","year":"2013","journal-title":"Endocrinology"},{"key":"ref681","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1159\/000126764","article-title":"Decreased expression of the two D2 dopamine receptor isoforms in bromocriptine-resistant prolactinomas","volume":"60","year":"1994","journal-title":"Neuroendocrinology"},{"key":"ref861","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1530\/EJE-11-0656","article-title":"Resistance to dopamine agonists in prolactinoma is correlated with reduction of dopamine D2 receptor long isoform mRNA levels","volume":"166","year":"2012","journal-title":"European Journal of Endocrinology"},{"key":"ref1221","first-page":"1252","article-title":"Somatostatin receptor scintigraphy in pituitary adenomas: a somatostatin receptor density index can predict hormonal and tumoral efficacy of octreotide in vivo","volume":"40","year":"1999","journal-title":"Journal of Nuclear Medicine"},{"key":"ref1391","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1210\/jc.2008-1008","article-title":"Treatment of pituitary-dependent Cushing\u2019s disease with the multireceptor ligand somatostatin analog pasireotide (SOM230): a multicenter, Phase II trial","volume":"94","year":"2009","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"ref151","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.mce.2007.09.006","article-title":"Pasireotide (SOM230): development, mechanism of action and potential applications","volume":"286","year":"2008","journal-title":"Molecular and Cellular Endocrinology"},{"key":"ref1551","first-page":"50","article-title":"Gender differences in macroprolactinomas: study of clinical features, outcome of patients and Ki-67 expression in tumor tissue","volume-title":"Frontiers of Hormone Research","year":"2010"},{"key":"ref281","first-page":"295","article-title":"Quantitative analysis of somatostatin receptor subtypes (1\u20135) gene expression levels in somatotropinomas and correlation to in vivo hormonal and tumor volume responses to treatment with octreotide LAR","year":"2008","journal-title":"European Journal of Endocrinology"},{"key":"ref511","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1210\/jc.2008-1008","article-title":"Treatment of pituitary-dependent Cushing\u2019s disease with the multireceptor ligand somatostatin analog pasireotide (SOM230): a multicenter, Phase II trial","volume":"94","year":"2009","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"ref1491","first-page":"1","article-title":"of of Practice guidelines for the management of aggressive pituitary tumours and carcinomas of https org","journal-title":"European Society Endocrinology European Society Endocrinology Clinical European Journal Endocrinology"},{"key":"ref1651","first-page":"9606985","article-title":"Expression of somatostatin receptor 2 in Somatotropinoma correlated with the short-term efficacy of somatostatin analogues","volume":"2017","year":"2017","journal-title":"International Journal of Endocrinology"},{"key":"ref1421","doi-asserted-by":"crossref","first-page":"2797","DOI":"10.1210\/jc.2002-021825","article-title":"Somatostatin receptor Subtype 1 selective activation in human growth hormone (GH)- and prolactin (PRL)-secreting pituitary adenomas: effects on cell viability, GH, and PRL secretion","volume":"88","year":"2003","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"ref421","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1210\/jc.2007-1358","article-title":"Correlation of in vitro and in vivo somatotropic adenoma responsiveness to somatostatin analogs and dopamine agonists with immunohistochemical evaluation of somatostatin and dopamine receptors and electron microscopy","volume":"93","year":"2008","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"ref1011","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1007\/s12020-015-0594-x","article-title":"The expression of the truncated isoform of somatostatin receptor subtype 5 associates with aggressiveness in medullary thyroid carcinoma cells","volume":"50","year":"2015","journal-title":"Endocrine"},{"key":"ref1691","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1055\/s-0034-1384520","article-title":"Filamin A in somatostatin and dopamine receptor regulation in pituitary and the role of cAMP\/PKA dependent phosphorylation","volume":"46","year":"2014","journal-title":"Hormone and Metabolic Research"},{"key":"ref821","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/j.1749-6632.2011.05985.x","article-title":"Truncated somatostatin receptors as new players in somatostatin-cortistatin pathophysiology","volume":"1220","year":"2011","journal-title":"Annals of the New York Academy of Sciences"},{"key":"ref1401","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1056\/NEJMoa1105743","article-title":"A 12-month Phase 3 study of pasireotide in Cushing\u2019s disease.","volume":"366","year":"2012","journal-title":"New England Journal of Medicine"},{"key":"ref401","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1210\/jc.2003-031344","article-title":"The novel somatostatin analog SOM230 is a potent inhibitor of hormone release by Growth Hormone- and prolactin-secreting pituitary adenomas in vitro","volume":"89","year":"2004","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"ref1141","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1210\/jc.2010-2443","article-title":"Place of cabergoline in acromegaly: a meta-analysis","volume":"96","year":"2011","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"ref1051","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/j.1365-2265.2008.03503.x","article-title":"Significant tumour shrinkage after 12 months of lanreotide Autogel-120 mg treatment given first-line in acromegaly","volume":"71","year":"2009","journal-title":"Clinical Endocrinology"},{"key":"ref1431","doi-asserted-by":"crossref","first-page":"5181","DOI":"10.1210\/jc.2003-031954","article-title":"Evidence for differential effects of selective somatostatin receptor subtype agonists on beta-subunit and chromogranin A secretion and on cell viability in human nonfunctioning pituitary adenomas in vitro","volume":"89","year":"2004","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"ref1541","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1530\/EC-15-0105","article-title":"Gender differences in macroprolactinomas: a single centre experience","volume":"5","year":"2016","journal-title":"Endocrine Connections"},{"key":"ref1581","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1530\/EJE-07-0806","article-title":"Somatostatinergic ligands in dopamine-sensitive and -resistant prolactinomas","volume":"158","year":"2008","journal-title":"European Journal of Endocrinology"},{"key":"ref1201","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1210\/jc.2007-1986","article-title":"Selective loss of somatostatin receptor 2 in octreotide-resistant Growth Hormone-secreting adenomas","volume":"93","year":"2008","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"ref951","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1210\/er.2000-0001","article-title":"The pathophysiological consequences of somatostatin receptor internalization and resistance","volume":"24","year":"2003","journal-title":"Endocrine Reviews"},{"key":"ref1331","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1007\/s11102-012-0445-1","article-title":"Growth Hormone granulation pattern and somatostatin receptor subtype 2A correlate with postoperative somatostatin receptor ligand response in acromegaly: a large single center experience","volume":"16","year":"2013","journal-title":"Pituitary"},{"key":"ref1711","first-page":"1","article-title":"BIM-23A760 influences key functional endpoints in pituitary adenomas and normal pituitaries: molecular mechanisms underlying the differential response in adenomas","volume":"7","year":"2017","journal-title":"Scientific Reports"},{"key":"ref1701","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/j.1749-6632.2011.05985.x","article-title":"Truncated somatostatin receptors as new players in somatostatin-cortistatin pathophysiology","volume":"1220","year":"2011","journal-title":"Annals of the New York Academy of Sciences"},{"key":"ref171","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/j.1365-2265.2008.03503.x","article-title":"Significant tumour shrinkage after 12 months of lanreotide Autogel-120 mg treatment given first-line in acromegaly","volume":"71","year":"2009","journal-title":"Clinical Endocrinology"},{"key":"ref741","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.endonu.2014.05.006","article-title":"Cytoplasmic expression of SSTR2 and 5 by immunohistochemistry and by RT\/PCR is not associated with the pharmacological response to octreotide","volume":"61","year":"2014","journal-title":"Endocrinologia y Nutricion"},{"key":"ref661","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1530\/EC-15-0105","article-title":"Gender differences in macroprolactinomas: a single centre experience","volume":"5","year":"2016","journal-title":"Endocrine Connections"},{"key":"ref371","first-page":"423","article-title":"111Indium-pentetreotide pituitary scintigraphy and hormonal responses to octreotide in acromegalic patients","volume":"20","year":"1997","journal-title":"Journal of Endocrinological Investigation"},{"key":"ref891","doi-asserted-by":"crossref","first-page":"2634","DOI":"10.1210\/jc.2008-2564","article-title":"Identification and characterization of two novel truncated but functional isoforms of the somatostatin receptor subtype 5 differentially present in pituitary tumors","volume":"94","year":"2009","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"ref1301","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1210\/jc.2007-1358","article-title":"Correlation of in vitro and in vivo somatotropic adenoma responsiveness to somatostatin analogs and dopamine agonists with immunohistochemical evaluation of somatostatin and dopamine receptors and electron microscopy","volume":"93","year":"2008","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"7862","DOI":"10.1074\/jbc.275.11.7862","article-title":"Subtypes of the somatostatin receptor assemble as functional homo- and heterodimers","volume":"275","year":"2000","journal-title":"Journal of Biological Chemistry"},{"key":"ref1561","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1159\/000126764","article-title":"Decreased expression of the two D2 dopamine receptor isoforms in bromocriptine-resistant prolactinomas","volume":"60","year":"1994","journal-title":"Neuroendocrinology"},{"key":"ref411","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1007\/s12022-007-9004-0","article-title":"Immunohistochemical detection of somatostatin receptor (sstr) subtypes 2A and 5 in pituitary adenoma from acromegalic patients: good correlation with preoperative response to octreotide","volume":"18","year":"2007","journal-title":"Endocrine Pathology"},{"key":"ref1321","doi-asserted-by":"publisher","first-page":"201398","DOI":"10.1210\/jc.2012-2609","article-title":"GattoFFeeldersRAVan Der PasRKrosJMWaaijersMSprij - MooijDNeggersSJCMMVan Der LelijAJMinutoFDe LambertsSWJImmunoreactivity score using an anti - sst receptor monoclonal antibody strongly predicts the biochemical response to adjuvant treatment with","journal-title":"Journal Clinical Endocrinology Metabolism"},{"key":"ref841","doi-asserted-by":"crossref","first-page":"4715","DOI":"10.1210\/en.2013-1672","article-title":"\u03b2-Arrestin 1 and 2 and G protein-coupled receptor kinase 2 expression in pituitary adenomas: role in the regulation of response to somatostatin analogue treatment in patients with acromegaly","volume":"154","year":"2013","journal-title":"Endocrinology"},{"key":"ref221","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0303-7207(03)00236-3","article-title":"Anti-proliferative effects and cell death mediated by two isoforms of dopamine D2 receptors in pituitary tumor cells","volume":"206","year":"2003","journal-title":"Molecular and Cellular Endocrinology"},{"key":"ref571","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1210\/jc.2008-1826","article-title":"Expression analysis of dopamine receptor subtypes in normal human pituitaries, nonfunctioning pituitary adenomas and somatotropinomas, and the association between dopamine and somatostatin receptors with clinical response to octreotide-LAR in acromegaly","volume":"94","year":"2009","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"ref651","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1530\/EJE-13-0503","article-title":"Giant prolactinomas in women","volume":"170","year":"2014","journal-title":"European Journal of Endocrinology"},{"key":"ref381","first-page":"2759","article-title":"Impact of gsp oncogene on the expression of genes coding for Gs\u03b1, Pit-1, Gi2\u03b1, and somatostatin receptor 2 in human somatotroph adenomas: involvement in octreotide sensitivity","volume":"84","year":"1999","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"ref441","doi-asserted-by":"publisher","first-page":"201398","DOI":"10.1210\/jc.2012-2609","article-title":"GattoFFeeldersRAVan Der PasRKrosJMWaaijersMSprij - MooijDNeggersSJCMMVan Der LelijAJMinutoFDe LambertsSWJImmunoreactivity score using an anti - sst receptor monoclonal antibody strongly predicts the biochemical response to adjuvant treatment with","journal-title":"Journal Clinical Endocrinology Metabolism"},{"key":"ref621","first-page":"1369","article-title":"Dopamine agonist\u2013resistant prolactinomas","volume":"114","year":"2011","journal-title":"Journal of Neurological Surgery"},{"key":"ref1001","doi-asserted-by":"crossref","first-page":"e85527","DOI":"10.1371\/journal.pone.0085527","article-title":"The truncated isoform of somatostatin receptor5 (sst5TMD4) is associated with poorly differentiated thyroid cancer","volume":"9","year":"2014","journal-title":"PLoS ONE"},{"key":"ref1521","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1530\/EJE-09-0012","article-title":"Characterization of resistance to the prolactin-lowering effects of cabergoline in macroprolactinomas: a study in 122 patients","volume":"160","year":"2009","journal-title":"European Journal of Endocrinology"},{"key":"ref1081","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1007\/s12020-016-0978-6","article-title":"Late-night salivary cortisol may be valuable for assessing treatment response in patients with Cushing\u2019s disease: 12-month, Phase III pasireotide study","volume":"54","year":"2016","journal-title":"Endocrine"},{"key":"ref1251","first-page":"423","article-title":"111Indium-pentetreotide pituitary scintigraphy and hormonal responses to octreotide in acromegalic patients","volume":"20","year":"1997","journal-title":"Journal of Endocrinological Investigation"},{"key":"ref1751","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1210\/jc.2011-2902","article-title":"Filamin-A is essential for dopamine d2 receptor expression and signaling in tumorous lactotrophs","volume":"97","year":"2012","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"ref1591","first-page":"3455","article-title":"Expression and localization of somatostatin receptor SSTR1, SSTR2, and SSTR3 messenger RNAs in primary human tumors using in situ hybridization","volume":"54","year":"1994","journal-title":"Cancer Research"},{"key":"ref721","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1007\/BF03351043","article-title":"Expression of somatostatin receptors on human pituitary adenomas in vivo and ex vivo","volume":"24","year":"2001","journal-title":"Journal of Endocrinological Investigation"},{"key":"ref731","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1046\/j.1365-2362.2001.00786.x","article-title":"Somatostatin receptor subtype 2 and 5 in human GH-secreting pituitary adenomas: analysis of gene sequence and mRNA expression","volume":"31","year":"2001","journal-title":"European Journal of Clinical Investigation"},{"key":"ref201","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1007\/s12020-016-0978-6","article-title":"Late-night salivary cortisol may be valuable for assessing treatment response in patients with Cushing\u2019s disease: 12-month, Phase III pasireotide study","volume":"54","year":"2016","journal-title":"Endocrine"},{"key":"ref181","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1507\/endocrj.EJ14-0118","article-title":"Short-term preoperative octreotide treatment for TSH-secreting pituitary adenoma","volume":"62","year":"2015","journal-title":"Endocrine Journal"},{"key":"ref111","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.canlet.2015.01.037","article-title":"Truncated somatostatin receptor variant sst5TMD4 confers aggressive features (proliferation, invasion and reduced octreotide response) to somatotropinomas","volume":"359","year":"2015","journal-title":"Cancer Letters"},{"key":"ref161","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1210\/jc.2008-1919","article-title":"Differential effects of octreotide and pasireotide on somatostatin receptor internalization and trafficking in vitro","volume":"94","year":"2009","journal-title":"Journal of Clinical Endocrinology and Metabolism"}],"container-title":["European Journal of Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/eje.bioscientifica.com\/view\/journals\/eje\/179\/5\/EJE-18-0549.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1530\/EJE-18-0549","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T16:12:24Z","timestamp":1676391144000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ejendo\/article\/179\/5\/D15\/6655389"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":176,"journal-issue":{"issue":"5"},"URL":"https:\/\/doi.org\/10.1530\/eje-18-0549","relation":{},"ISSN":["0804-4643","1479-683X"],"issn-type":[{"value":"0804-4643","type":"print"},{"value":"1479-683X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11]]}}}